Tocilizumab for severe COVID‐19 pneumonia: Case series of 5 Australian patients

Abstract

Tocilizumab use was associated with favorable clinical outcome in our patients. We recommend tocilizumab be included in randomized controlled trials of treatment for patients with severe COVID-19 pneumonia, and be considered for compassionate use in such patients pending the results of these trials.